These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11773185)

  • 21. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
    Vercaigne LM; Zacharias J; Bernstein KN
    Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interventions for restoring patency of occluded central venous catheter lumens.
    van Miert C; Hill R; Jones L
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD007119. PubMed ID: 22513946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters.
    Atkinson JB; Bagnall HA; Gomperts E
    JPEN J Parenter Enteral Nutr; 1990; 14(3):310-1. PubMed ID: 2112648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases.
    Molinari AC; Haupt R; Saracco P; Di Marco M; Castagnola E; Fratino G
    Support Care Cancer; 2004 Dec; 12(12):840-3. PubMed ID: 15365798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reteplase for dysfunctional hemodialysis catheter clearance.
    Hilleman DE; Dunlay RW; Packard KA
    Pharmacotherapy; 2003 Feb; 23(2):137-41. PubMed ID: 12587800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of management of CVAD occlusions.
    Peng C; Monagle P; Newall F
    Arch Dis Child; 2011 Sep; 96(9):885-7. PubMed ID: 21398316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase administration in pediatric patients with occluded central venous catheters.
    Wachs T
    J Intraven Nurs; 1990; 13(2):100-2. PubMed ID: 2313458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
    Jacobs BR; Haygood M; Hingl J
    J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.
    Daeihagh P; Jordan J; Chen J; Rocco M
    Am J Kidney Dis; 2000 Jul; 36(1):75-9. PubMed ID: 10873875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients.
    MacLean J; MacDonald T; Digout C; Smith N; Rigby K; Kulkarni K
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27015. PubMed ID: 29537717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of alteplase for restoring patency to occluded central venous access devices in infants and children.
    Fisher AA; Deffenbaugh C; Poole RL; Garcia M; Kerner JA
    J Infus Nurs; 2004; 27(3):171-4. PubMed ID: 15118455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
    Moll S; Kenyon P; Bertoli L; De Maio J; Homesley H; Deitcher SR
    J Clin Oncol; 2006 Jul; 24(19):3056-60. PubMed ID: 16809729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
    Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
    Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
    Eyrich H; Walton T; Macon EJ; Howe A
    Am J Health Syst Pharm; 2002 Aug; 59(15):1437-40. PubMed ID: 12166043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: the ALTE-DOSE study.
    Yaseen O; El-Masri MM; El Nekidy WS; Soong D; Ibrahim M; Speirs JW; Kadri A
    Hemodial Int; 2013 Jul; 17(3):434-40. PubMed ID: 23176161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
    Haire WD; Atkinson JB; Stephens LC; Kotulak GD
    Thromb Haemost; 1994 Oct; 72(4):543-7. PubMed ID: 7878629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures.
    Savader SJ; Ehrman KO; Porter DJ; Haikal LC; Oteham AC
    J Vasc Interv Radiol; 2001 Jun; 12(6):711-5. PubMed ID: 11389222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
    Dillon PW; Jones GR; Bagnall-Reeb HA; Buckley JD; Wiener ES; Haase GM;
    J Clin Oncol; 2004 Jul; 22(13):2718-23. PubMed ID: 15226339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.